



NOMINATIONS ARE INVITED
for the prestigious
InBev-BAILLET LATOUR
HEALTH PRIZE
of
€ 250,000

(Two hundred and fifty thousand euros)

Theme for 2012 : **Neurosciences**

Previous winner : Peter H. Seeburg, Germany

This annual award is intended to recognize outstanding scientific achievements in biomedical research and/or their practical applications for human health and to encourage the laureate in the pursuit of his/her career. Exceptionally, the Prize may be shared between two persons who have collaborated over a long period. The laureate will be selected by an international Jury in February 2012.

The Prize is open to scientists of all nationalities who have not received in their own name an equivalent Prize rewarding the work that is submitted. The themes for the following years will be : Cancer, Cardiovascular Diseases, Metabolic Disorders, Infectious Diseases and Immunology.

Deadline for nominations : September 30th, 2011

Nominations must be submitted in an envelope marked "Confidential" to the Secretary General of the Fund for Scientific Research-FNRS, rue d'Egmont 5, BE - 1000 Brussels, Belgium and postmarked no later than **September 30th, 2011**.

Regulations and nomination forms can be obtained by e-mail from chantal.mairesse@frs-fnrs.be

Contact :
Tél. : +32.2.504.92.40 (45)
Fax : +32.2.504.92.10
chantal.mairesse@frs-fnrs.be

INBEV-BAILLET LATOUR **HEALTH PRIZE 2012**

REGULATIONS

1. THE "INBEV-BAILLET LATOUR HEALTH PRIZE 2012"

The Management Board of the InBev-Baillet Latour Fund has decided that the theme of the InBev-Baillet Latour Health Prize 2012 will be "**Neurosciences**". The themes for the next four years will be "Cancer", "Cardiovascular Diseases", "Metabolic Disorders", "Infectious Diseases and Immunology".

The current value of the Prize is € 250,000 (two hundred and fifty thousand euros).

2. NOMINATIONS

The Prize is awarded every year for outstanding achievements in biomedical research and/or their practical applications for human health. The Prize was established to recognize scientific merits and to encourage the laureate in the pursuit of his/her creative research. Hence the Prize is intended for currently active biomedical scientists.

Exceptionally, the Prize may be shared between two persons who have closely collaborated over a long period of time.

The Prize is open to scientists of all nationalities who have not previously received in their own name an equivalent Prize rewarding the work that is submitted for the InBev-Baillet Latour Health Prize.

The candidate must be nominated by one person duly qualified to appreciate the nominee's work, using the form provided at www.inbevbaillatour.com or at www.frs-fnrs.be/fr/financer-les-chercheurs/prix-scientifiques/prix-biomedical.html or by the Fund for Scientific Research-FNRS, rue d'Egmont 5, 1000 Brussels, Belgium (e-mail to chantal.mairesse@frs-fnrs.be).

The main scientific contributions of the nominee, their relevance for the theme of biomedical science indicated and their possible implications for the improvement of human health should be summarized on the form, as instructed.

. / . .

- 2 -

A list of the five most important publications (excluding books and reviews) of the nominee(s) and a copy of these five papers should be added to the form.

A curriculum vitae and a list of her/his peer-reviewed publications (with exclusion of conference talks and abstracts) should also be added.

The nomination file for 2012 must be sent in an envelope marked "Confidential" to the Secretary General of the Fund for Scientific Research-FNRS, rue d'Egmont 5, BE - 1000 Brussels, Belgium and postmarked no later than **September 30th 2011** (*this is a strict deadline*).

3. THE JURY

The jury is appointed by the Scientific Committee of the InBev-Baillet Latour Health Prize. It consists of at least six non-Belgian and one Belgian scientists who are experts in the field of research chosen as theme of the Prize. The Scientific Committee selects as Chairperson one of the non-Belgian members of the jury.

4. ADMINISTRATIVE INFORMATION

The Fund for Scientific Research-FNRS is entitled to settle any questions related to the admissibility of the applications. The awarding of the Prize will be final, without appeal. Nominations and reports relative to the award of the InBev-Baillet Latour Health Prize may neither be revealed nor published.

11.4.2011

Contact :
Tél. : +32.2.504.92.40 (45)
Fax : +32.2.504.92.10
chantal.mairesse@frs-fnrs.be

THE INBEV-BAILLET LATOUR HEALTH PRIZE - 2012

HISTORICAL BACKGROUND

1. THE FOUNDATION

The ARTOIS-BAILLET LATOUR Foundation was established on the 1st of March 1974 at the initiative of Count Alfred de BAILLET LATOUR, Director of the ARTOIS Breweries, who presented it with a considerable endowment. The aim of the Foundation was defined as follows :

"The sole aim of the Foundation shall be to encourage and reward achievements of outstanding human value in the Arts and Sciences by means of Prizes, study and travel grants, donations in cash or kind, or by any other means that the Foundation might deem appropriate. The Foundation shall be a non-profit institution and shall have no political, trade-union, philosophical or religious affiliation or allegiance".

The Foundation was initially called "Artois Baillet Latour Foundation". In 1995 it became the "Interbrew-Baillet Latour Foundation" and in 2005, the "InBev-Baillet Latour Fund". The Board of Directors became the Management Board. It is chaired by Mr Jan HUYGHEBAERT, Chairman of the Board of Directors of KBC Group.

2. THE PRIZE

To implement the wishes of Count Alfred de BAILLET LATOUR, the Board of Directors of the Foundation decided in 1977 to establish a Prize to be awarded periodically to recognize the merits of a person whose work has contributed prominently to the **improvement of human health**. The Prize was called *ARTOIS-BAILLET LATOUR HEALTH PRIZE* until 1995, then *INTERBREW-BAILLET LATOUR HEALTH PRIZE* and from 2005 on *INBEV-BAILLET LATOUR HEALTH PRIZE*. This Prize, which today amounts to **two hundred and fifty thousand euro**, was awarded every other year until 1999, and every year since 2000.

Since 2006 the Prize is awarded for one specific domain of medical research selected every year from the following themes : Neurosciences (2012), Cancer (2013), Cardiovascular diseases (2014), Metabolic disorders (2015), Infectious diseases and Immunology (2016).

. / . .

The regulations concerning the Prize are approved by the Management Board of the Fund. In 2006, the scientific management and selection of the international jury of the Prize were delegated to a SCIENTIFIC COMMITTEE. This Committee receives administrative support from the Fund for Scientific Research-FNRS (Belgium). Its current composition is as follows : Professors Guy ROUSSEAU (President), Jacques BROTCHE, Désiré COLLEN, Jean-Michel FOIDART, Louis HUE, Geert LEROUX-ROELS.

3. FORMER PRIZEWINNERS

- **1979 : Sir James W. BLACK** (Great-Britain) for contribution to the development of drugs for the treatment of cardiovascular disorders and gastro-intestinal diseases.
- **1981 : Sir Cyril A. CLARKE** (Great-Britain) for basic and clinical contributions to the control of Rhesus haemolytic disease of the newborn.
- **1983 : Professor Jean BERNARD** (France) for contributions to the treatment of acute leukaemias and hematosarcomas.
- **1985 : Professor Johannes J. van ROOD** (The Netherlands) for contribution to the discovery of the genes and antigens of the major histocompatibility complex of man.
- **1987 : Professors Viktor MUTT and Tomas HÖKFELT** (Sweden) for complementary contributions to the elucidation of neuropeptide function.
- **1989 : Professor Walter FIERS** (Belgium) for contributions to molecular virology and the isolation and expression of lymphokine genes.
- **1991 : Professor Thomas WALDMANN** (United States of America) for contributions to the use of monoclonal antibodies in diagnosis and immunotherapy.
- **1993 : Professor Jean-François BOREL** (Switzerland) for discovery of the immunosuppressive agent cyclosporin.
- **1995 : Professor Roger TSIEN** (United States of America) for contribution to the discovery of intracellular signals which are critical for the action of hormones, neurotransmitters, mediators of immunity, and growth factors.
- **1997 : Professor Michael SELA** (Israel) for the development of chemically-built peptides that regulate the immune response and of vaccines that could interfere with autoimmune diseases such as multiple sclerosis.
- **1999 : Professor Julien MENDLEWICZ** (Belgium) for studies of the genetic basis of manic-depressive psychosis and identification of genetically-based disorders of biological rhythms, sleep and hormone secretion.
- **2000 : Professors Jacques VAN SNICK and Jean-Christophe RENAULD** (Belgium) for contributions to the field of cytokines in relation to the regulation of cell proliferation and immune response.

- **2001 : Dr Jan D.A. van EMBDEN** (The Netherlands) for work on the rôle of heat shock proteins in inflammation and the genetic characterization of Mycobacterium tuberculosis.
- **2002 : Professor Robert M. KRUG** (United States of America) for the discovery of cap-snatching and its importance in viral replication.
- **2003 : Professor Nancy C. ANDREASEN** (United States of America) for contributions to the identification, mechanisms and treatment of schizophrenia.
- **2004 : Professor Elio LUGARESI** (Italy) for contribution to the field of sleep disorders and discovery of the rôle of Prion gene mutation in Fatal Familial Insomnia.
- **2005 : Professors Désiré COLLEN and Peter CARMELIET** (Belgium) for pioneering work in genetic engineering, development of recombinant tissue plasminogen activator and generation of animal models of human cardiac diseases.
- **2006 : Professor Hidde L. PLOEGH** (United States of America) for work on how cells eliminate misfolded proteins and how viruses evade immune responses.
- **2007 : Professor Peter H. SEEBURG** (Germany) for discovery of fundamental mechanisms of neural transmission in the brain.
- **2008 : Professor Robert A. WEINBERG** (United States of America) for contributions to the field of molecular oncology, including the identification of the retinoblastoma tumor suppressor gene and of mechanisms underlying tumor progression and metastasis.
- **2009 : Professors Kari ALITALO and Seppo YLÄ-HERTTUALA** (Finland) for contributions in the field of angiogenesis and lymphangiogenesis and their modulation by signaling pathways.
- **2010 : Professor Stephen O'RAHILLY** (United Kingdom) for contributions to our understanding of how alterations in single genes can cause metabolic disorders, especially obesity, in humans.
- **2011 : Professor Jean-Laurent CASANOVA** (United States of America) for pioneering work on the identification of genes that predispose to human infectious diseases.

Contact :
Tél. : +32.2.504.92.40 (45)
Fax : +32.2.504.92.10
chantal.mairesse@frs-fnrs.be

**NOMINATION FORM
INBEV-BAILLET LATOUR HEALTH PRIZE 2012
"Neurosciences"**

Submission Deadline : September 30, 2011

CANDIDATE

Surname _____ First name _____

Date of birth _____ Nationality _____

Position and title _____

Professional address _____

Phone _____ E-mail _____

NOMINATED BY

Surname _____ First name _____

Nationality _____ Position and title _____

Address _____

Phone _____ Date _____

E-mail _____ Signature _____

1.4.2011

Nominations should be typewritten in English and include the following :

- a **curriculum vitae** of the nominee and a list of her/his peer-reviewed **publications** (excluding conference talks and abstracts).
- a list of her/his **five most important publications** (excluding books and reviews) and a **copy** of these five papers.
- in the **box below (use font size 11 ; do not exceed the space allowed) summarize** the main scientific achievements and current research activities of the nominee, and their relevance for the theme indicated. Outline how this work stands out in the field and its possible implications for the improvement of human health.